Conventional immunotherapy

Harnessing Your Immune System to Fight Cancer

Checkpoint inhibitors, monoclonal antibodies, and therapeutic vaccines offering new hope for cancer patients

Immunotherapy

What is conventional immunotherapy?

Cancer immunotherapy is a treatment approach that activates the patient's own immune system to recognize and destroy cancer cells. Unlike traditional chemotherapy that directly kills cancer cells, immunotherapy "releases the brakes" on the immune system, allowing it to fight cancer more effectively.

Cancer cells often use "immune escape" mechanisms to hide from the immune system. Immunotherapy drugs help overcome this by blocking these escape pathways, restoring the immune system's ability to detect and eliminate cancer cells.

Back to Therapies Contact Us

Types of Immunotherapy

Various immunotherapy approaches to suit different cancer types and patient needs

Immune Checkpoint Inhibitors

PD-1/PD-L1 inhibitors "release the brakes" on T cells, restoring their cancer-fighting ability. CTLA-4 inhibitors activate T cell immune response. These are the most commonly used immunotherapy drugs.

Monoclonal Antibodies

Precisely target tumor antigens or microenvironment targets. Can mark cancer cells for immune destruction or block growth signals that cancer cells need to proliferate.

Therapeutic Vaccines

Activate specific immune responses against tumors. Examples include HPV vaccines for cervical cancer prevention and treatment.

Cytokine Therapy

Directly enhance immune cell activity. Used for melanoma, kidney cancer, and other malignancies with proven efficacy.

China's Immunotherapy Leadership

China has emerged as a global leader in immunotherapy development and clinical application

1000+
Clinical Trials in China
(35% of global total)
16+
Domestic PD-1 Inhibitors
Approved
40-60%
Response Rate in
PD-L1 High Patients

Treatment Indications

  • Non-Small Cell Lung Cancer

    One of the most successful applications of immunotherapy with high response rates

  • GI Cancers

    Gastric, esophageal, colorectal (MSI-H/dMMR), and liver cancers

  • Melanoma

    First-line treatment for advanced or metastatic melanoma

  • Other Solid Tumors

    Head and neck squamous cell carcinoma, renal cancer, bladder cancer, Hodgkin lymphoma

Key Advantages

  • Precise Targeting

    Minimal damage to normal cells with mild side effects

  • Durable Response

    Can induce immune memory for long-term cancer control

  • Broad Application

    One drug can potentially treat multiple cancer types

  • Combination Potential

    Can be combined with chemotherapy, radiation, or targeted therapy

Explore Immunotherapy Options

Contact us for personalized immunotherapy consultation

Consult Now